Recent studies demonstrated that SARS-CoV-2 can stimulate neutrophils directly through the ACE2-TMPRSS2 axis to induce release of NETs, thus presenting a potential therapeutic approach to inhibit NETs and its associated devastating complications in severe COVID-19 patients (35). The gene discussed is TMPRSS2; the disease is COVID-19.